Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
DSS Continues to Grow its Healthcare Segment through $1M Investment in Vivacitas Oncology
Details : Vivacitas' lead development candidate (AR-67) is a novel lipophilic next-generation camptothecin (Topiosomerase-1 enzyme inhibitor) compound with the potential to deliver improved efficacy and tolerability, employing a proprietary synthesis method.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 02, 2021
Lead Product(s) : Silatecan
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : IAG, Image Analysis Group
Deal Size : Undisclosed
Deal Type : Partnership
Details : The companies are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67, a third generation Camptothecin, in patients with recurrent glioblastoma multiforme (reGBM).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 03, 2021
Lead Product(s) : Silatecan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : IAG, Image Analysis Group
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
